Content about Endocrine system

October 19, 2011
Takeda launches late-stage trial program for Type 2 diabetes drug

Takeda Pharmaceuticals has started a late-stage clinical trial program for a drug to treat Type 2 diabetes, the drug maker said.

OSAKA, Japan — Takeda Pharmaceuticals has started a late-stage clinical trial program for a drug to treat Type 2 diabetes, the drug maker said.

September 30, 2011
Novo Nordisk seeks to market insulin products

Novo Nordisk is seeking approval for two new insulin products, the company said Thursday.

PRINCETON, N.J. — Novo Nordisk is seeking approval for two new insulin products, the company said Thursday.

Novo Nordisk announced that it had filed with the Food and Drug Administration for approval of insulin degludec and a co-formulation of insulin degludec and insulin aspart. The products are insulin analogs developed for the treatment of Type 1 and Type 2 diabetes.

September 27, 2011
Sam's Club to offer free thyroid health tests for women

Mass merchandiser Sam's Club is offering a free women's health screening in recognition of Breast Cancer Awareness Month, the chain said Tuesday.

BENTONVILLE, Ark. — Mass merchandiser Sam's Club is offering a free women's health screening in recognition of Breast Cancer Awareness Month, the chain said Tuesday.

September 13, 2011
Study: Sanofi insulin reduces weight gain, increases blood sugar control

An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

PARIS — An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

September 8, 2011
JDRF, InnoCentive launch challenge for treatment of diabetes

The Juvenile Diabetes Research Foundation and InnoCentive are calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat Type 1 diabetes.

WALTHAM, Mass. — The Juvenile Diabetes Research Foundation and InnoCentive are calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat Type 1 diabetes.

August 30, 2011
Editorial questions study on atmospheric pressure's influence on insulin pump devices

More evidence may be needed to support research that implied that atmospheric pressure during airplane travel could influence the effectiveness of insulin pump devices, according to an editorial published in Diabetes Technology & Therapeutics.

NEW ROCHELLE, N.Y. — More evidence may be needed to support research that implied that atmospheric pressure during airplane travel could influence the effectiveness of insulin pump devices, according to an editorial published in Diabetes Technology & Therapeutics.

August 12, 2011
Spices may reduce insulin, triglyceride response, research finds

Adding spices to a meal can help reduce insulin and triglyceride response, according to new research published in the Journal of Nutrition.

UNIVERSITY PARK, Pa. — Adding spices to a meal can help reduce insulin and triglyceride response, according to new research published in the Journal of Nutrition.

August 10, 2011
Study: Soy supplementation ineffective versus relief of menopausal symptoms

Soy isoflavone tablets do not appear to be associated with a reduction in bone loss or menopausal symptoms in women within the first five years of menopause, according to a report in the Aug. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

MIAMI — Soy isoflavone tablets do not appear to be associated with a reduction in bone loss or menopausal symptoms in women within the first five years of menopause, according to a report in the Aug. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

August 1, 2011
Lilly, Lupin enter diabetes partnership

Eli Lilly’s India division and Indian generic drug maker Lupin will distribute Lilly’s insulin products in India and Nepal under an agreement between the two companies announced Friday.

NEW DELHI — Eli Lilly’s India division and Indian generic drug maker Lupin will distribute Lilly’s insulin products in India and Nepal under an agreement between the two companies announced Friday.

Under the collaboration, Lilly and Lupin will promote and distribute Huminsulin R, Huminsulin NPH, Huminsulin 50/50, Huminsulin 30/70 and Humapen Ergo II. The companies said the deal would double the current customer base.

July 6, 2011
MannKind: Patients have better view of insulin therapy when using Afrezza

Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

June 29, 2011
Lilly: Axiron improves hypogonadism symptoms among men

A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.

INDIANAPOLIS — A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.

Lilly announced results of a phase-3 trial of Axiron (testosterone) topical solution, a treatment for the condition, also known as hypogonadism. Study results also showed that the drug improved symptoms associated with it.

Hypogonadism results from damage or disease of the testicles, hypothalamus or pituitary glands that inhibits production of testosterone.

June 28, 2011
Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions

A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.

PARIS — A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.

Sanofi announced results of the 60-week study, which compared regimens, including Lantus (insulin glargine [rDNA origin]) and Apidra (insulin glulisine [rDNA origin]).

June 27, 2011
FDA accepts regulatory filing for Prochieve

The Food and Drug Administration has accepted a regulatory approval application for a drug designed to prevent premature birth in pregnant women.

LIVINGSTON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug designed to prevent premature birth in pregnant women.

Columbia Labs and Watson Pharmaceuticals announced Monday that the FDA would review their application for Prochieve (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the third trimester of pregnancy.

June 27, 2011
Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment

An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

SAN DIEGO — An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

The company conducted a study comparing the cost-effectiveness of LAIA, insulin lispro mix 75/25 and insulin lispro mix 50/50 in patients with Type 2 diabetes. Lilly sells insulin lispro under the brand name Humalog.

June 20, 2011
Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 17, 2011
Liraglutide may prompt optimal blood-glucose levels in Type 1 diabetics

A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

BUFFALO, N.Y. — A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

June 13, 2011
Study finds possible link between ADT, diabetes

Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

BOSTON — Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

June 9, 2011
FDA approves labeling change for Eli Lilly insulin product

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

June 6, 2011
Hypoglycemic events can disrupt work productivity for diabetics, survey finds

A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

COPENHAGEN, Denmark — A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

June 6, 2011
Study: Amylin's metreleptin improves diabetes, lipid control among patients

An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.

SAN DIEGO — An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.

Amylin Pharmaceuticals announced Saturday results of a study of metreleptin, an analog of the human hormone leptin. Results of the study were presented at the 93rd annual meeting and expo of the Endocrine Society in Boston.

June 2, 2011
Insulet acquires Neighborhood Diabetes

A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

BEDFORD, Mass. — A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

June 1, 2011
FDA to examine possible link between drospirenone, blood clots risk

The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

May 31, 2011
Sanofi: Lyxumia won't significantly increase hypoglycemia risk

New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

May 24, 2011
American Diabetes Association announces new research grant for diabetes technology

The American Diabetes Association announced that it will fund research that will examine the effectiveness of technology-based diabetes management devices.

ALEXANDRIA, Va. — The American Diabetes Association announced that it will fund research that will examine the effectiveness of technology-based diabetes management devices.

The studies, funded by the American Diabetes Association/Medtronic Technology in Diabetes Fellowship, will utilize Medtronic's CareLink database — a database of anonymous continuous glucose monitoring and insulin pump-derived data — to assess, evaluate and correlate the application of this and similar technologies used by patients with insulin-treated diabetes.

May 23, 2011
New ovulation test tracks LH levels

Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.

PRINCETON, N.J. — Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.